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A B S T R A C T
Staphylococcus aureus isolates were screened for
reduced susceptibility to glycopeptides with an
initial glycopeptide agar screening test, followed
by confirmation of the strains thus identified by
two Etest strip techniques and population analy-
sis. This procedure detected 48 methicillin-resist-
ant S. aureus (MRSA) isolates with reduced
susceptibility to glycopeptides from 24 patients
among 883 MRSA isolates tested. The dissemin-
ation of a single clone was confirmed by pulsed-
field gel electrophoresis.
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The glycopeptides vancomycin and teicoplanin
are the drugs of choice for the treatment of
infections caused by methicillin-resistant Staphy-
lococcus aureus (MRSA). Isolates of glycopeptide-
intermediate S. aureus (GISA) have been reported
from Japan with homogeneous glycopeptide
resistance of 8 mg ⁄L [1]. Heterogenous resistance
to glycopeptides was also described subsequently
by Hiramatsu et al. [2]. Heterogeneously glyco-
peptide-intermediate S. aureus (h-GISA) strains
are defined as strains of S. aureus containing sub-
populations of vancomycin-resistant daughter
cells, for which the apparent vancomycin MICs
of the parent strain are only 1–4 mg ⁄L. These sub-
populations typically have MICs that are 2–8-fold
higher than that for the original clinical isolate [3].
h-GISA strains have been reported from Japan
and various other countries, including the USA,
Thailand and France [4–6]. In this study, the
status of susceptibility to glycopeptides was
analysed among MRSA nosocomial isolates from
Chambe´ry, France.
In total, 883 consecutive MRSA strains isolated
from various clinical samples at Chambe´ry Hos-
pital in France were collected between January
2000 and March 2001 and stored in liquid nitro-
gen at )80 C. Three control strains were used:
S. aureus ATCC 29213 as the vancomycin-suscept-
ible control strain, and S. aureus Mu 50 and
S. aureus Mu 3 (both donated by K. Hiramatsu,
Justendo University, Tokyo, Japan) as the GISA
and h-GISA control strains, respectively.
Each MRSA isolate was screened initially on
Mueller–Hinton agar containing teicoplanin
5 mg ⁄L, as recommended by the French Micro-
biology Society [7]. A suspension equivalent to
2· McFarland standard was prepared from an
18–24-h culture in brain–heart infusion broth and
spotted (10 lL) on the teicoplanin-containing agar.
Incubation was at 35 C for 48 h. Glycopeptide
agar screening plates were prepared each week.
Control strains Mu 3 and Mu 50 were tested
weekly; strain ATCC 29213 was tested daily.
Isolates that yielded growth on the initial
screen were examined further with Etests (AB
Biodisk, Solna, Sweden) according to the manu-
facturer’s instructions. Etest screening was per-
formed with 200 lL of a dense inoculum (2·
McFarland standard) spread on brain–heart infu-
sion agar. Vancomycin and teicoplanin Etest
strips were placed on the inoculated agar and
incubated for 48 h at 35 C. The interpretative
breakpoints used for h-GISA or GISA with this
method were vancomycin ‡ 8 mg ⁄L and ⁄ or tei-
coplanin ‡ 8 mg ⁄L, as recommended by the
manufacturer at the time of this study. In addi-
tion, MICs were determined by Etest with a less
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dense inoculum (0.5· McFarland standard) on
Mueller–Hinton agar.
Population analysis of four putative h-GISA
isolates identified by the above methods was
performed according to the method of Howe et al.
[8]. Briefly, aliquots of an overnight culture were
inoculated on agar containing a range of vanco-
mycin concentrations (1–12 mg ⁄L). After incuba-
tion for 48 h, the colonies on each plate were
counted and plotted. The relationship between
selected h-GISA isolates was investigated by
generating SmaI macrorestriction patterns with a
contour-clamped homogeneous electric field sys-
tem (CHEF DR II; Bio-Rad, Hercules, CA, USA) as
described previously [9]. Comparison of resolved
macrorestriction patterns was based on the rec-
ommendations of Tenover et al. [10].
Of 883 MRSA isolates examined, 102 (11.6%)
from 58 patients yielded growth on glycopeptide
agar screening. With the high-inoculum Etest
screening method on brain–heart infusion agar,
14 isolates had a vancomycin MIC of ‡ 8 mg ⁄L,
while 48 isolates had a teicoplanin MIC of
‡ 8 mg ⁄L. All 14 strains positive by the vancomy-
cin Etest screening method were also positive by
the teicoplanin Etest screen. Fig. 1 shows the Etest
MICs for the 48 strains positive by the Etest
screening method. The other 54 strains identified
by the initial glycopeptide agar screen had vanco-
mycin and teicoplanin Etest MICs of £ 2 mg ⁄L.
The h-GISA character was confirmed by a
population analysis study of the first four isolates
from different patients that were positive in the
Etest screens (two positive only in the teicoplanin
screen and two positive with both glycopeptides)
(Fig. 2). All other strains recognised by the Etest
methods were also considered to be h-GISA, as all
these strains exhibited identical antibiograms
(resistance to penicillin, oxacillin, rifampicin,
erythromycin, lincomycin, tetracycline, kanamy-
cin, tobramycin, gentamicin and pefloxacin, with
susceptibility or reduced susceptibility to fosfo-
mycin and fusidic acid). In support of this
conclusion, population analysis of the three
S. aureus isolates with the same antibiogram that
were negative in the Etest screen indicated that
these three isolates were not h-GISA. Thus,
48 (5.4%) isolates were considered to be h-GISA.
These 48 isolates were from 24 patients hospi-
talised in eight different units: 16 patients were
colonised, while eight patients were infected (four
urinary tract infections, one bronchopulmonary
infection, two surgical wound infections and one
case of septicaemia). Analysis of SmaI macrore-
striction profiles of six isolates from six patients
hospitalised in different units indicated that all
the isolates belonged to a single clone.
The incidence of h-GISA strains remains low in
France (0.8% in Lyon, 0.6% in St-Etienne),
although several outbreaks have been described
[5,11,12]. The incidence of h-GISA in the present
study appears high, and also corresponds to an
outbreak. A separate epidemiological survey iden-
tified an index case from another hospital known
to have a problem with h-GISA strains. The
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Fig. 1. Glycopeptide MICs of 48 Staphylococcus aureus
strains positive by the Etest screening method.
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present study emphasised the difficulty of identi-
fying such strains. The glycopeptide susceptibility
of the isolates could not be assessed adequately
with the standard antibiogram procedure because
such strains do not fall into the category of
intermediate glycopeptide susceptibility, as
defined by the National Committee of the French
Microbiology Society. The glycopeptide MICs for
these isolates were 2–4-fold greater than for other
MRSA isolates [13]. The initial screening method
involving agar plates containing teicoplanin
5 mg ⁄L, with subsequent confirmation of positive
results by Etest screens and MIC determinations,
appears to be suitable for detection of h-GISA
strains. In cases where MIC values are at the limit
of discrimination, population analysis remains the
reference method. In the present study, growth of
54 isolates determined subsequently not to be
h-GISA was observed on the initial agar screening
plate. Thus, the specificity of this plate was not
optimal. However, an isolate was considered to be
positive even when only one colony was found.
The specificity would probably be increased if the
agar screening test was considered positive only
with growth of three or more S. aureus colonies on
the plate [14].
Finally, special screening for h-GISA strains is
necessary, since the glycopeptide susceptibility of
these multiresistant strains cannot be assessed
adequately by standard antibiogram procedures.
These strains must be identified in order to
prevent their dissemination within and between
hospitals. In this context, the screening method
used appears to be suitable and, because of its
ease of use and low costs, it can be used readily in
all hospitals.
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